Third Quarter Guidance (Wood Products) -- EBITDA expected to be $20 million-$30 million; EWP volume to decline high single ...

A national workshop on lightning risk reduction on Monday called for strengthened preparedness, faster early warning ...

The US Navy’s Zumwalt-class destroyers are about to undergo a dramatic transformation. These angular, futuristic warships — ...

On Friday, Oregon’s U.S. Senators Jeff Merkley and Ron Wyden, along with U.S. Representatives Val Hoyle (OR-04), Janelle ...

In a virtual Key Opinion Leader (KOL) roundtable hosted today, Entera Bio (Nasdaq: ENTX) convened globally recognized ...

The University of Alabama at Birmingham’s Biomedical Sciences bachelor’s program is proud to launch its new Biotechnology minor. From cells to solutions, this minor equips its students with science ...

Investing.com - Truist Securities reiterated a Buy rating and $46.00 price target on Edgewise Therapeutics (NASDAQ:EWTX) following an update from the company’s ongoing clinical trial. Edgewise ...

Edgewise Therapeutics' valuation is heavily reliant on DMD/BMD programs, with upcoming phase-2 readouts likely to disappoint and trigger a sharp stock decline. We believe that sevasemten's mechanism ...

Edgewise Therapeutics (EWTX) is building itself up as a good long-term biotech to hang onto. Especially, when you consider that it was able to report positive results from its phase 2 CANYON study, ...

JERUSALEM, March 26, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of orally delivered peptides, announced today that The American ...